業績一覧

HOME > 業績集 > 腎・高血圧グループ

腎・高血圧グループの業績一覧

Seiji Umemoto*, Toshio Ogihara*, Hiromi Rakugi*, Masayasu Matsumoto*, Kazuo Kitagawa*, Kazuyuki Shimada*, Jitsuo Higaki, Sadayoshi Ito*, Hiromichi Suzuki*,Yasuo Ohashi*,
Takao Saruta*, Masunori Matsuzaki* and on behalf of the Combination Therapy of
Hypertension to Prevent Cardiovascular Events Trial Group.

Effects of a Benidipine-Based Combination Therapy on the Risk of Stroke According to Stroke Subtype: the COPE Trial.

Hypertension Research 36: 1088-1095,2013.

⇒Detail

Tomoaki Nagao, Takafumi Okura, Jun Irita, Masanori Jotoku, Daijiro Enomoto, Veena Rasika Desilva, Ken-ichi Miyoshi, Mie Kurata, Yutaka Matsui*, Toshimitsu Uede*, Jitsuo Higaki.

Osteopontin Plays a Critical Role in Interstitial Fibrosis but Not Glomerular Sclerosis in Diabetic Nephropathy.

Nephron Extra 2: 87-103,2012.

⇒Detail

Daijiro Enomoto, Takafumi Okura, Tomoaki Nagao, Masanori Jotoku, Jun Irita, Ken-ichi Miyoshi, Jitsuo Higaki.

Relationship Between Renal Hemodynamics and Urinary TypeⅣ Collagen in Patients with Essential Hypertension.

Clinical and Experimental Hypertension 34: 612-616,2012.

⇒Detail

Mie Kurata, Takafumi Okura, Yoshiaki Kumon*, Masahiko Tagawa*, Hideaki Watanabe*, Toshinori Nakahara*, Tatsuhiko Miyazaki*, Jitsuo Higaki, Masato Nose*.

Plasma Thrombin-Cleaved Osteopontin Elevation after Carotid Artery Stenting in Symptomatic Ischemic Stroke Patients.

Hypertension Research 35: 207-212,2012.

⇒Detail

Takashi Moritoyo*, Tomoko Hasunuma*, Kazuhiro Harada*, Tomonori Tateishi*,Makoto Watanabe*, Tsutomu Kotegawa*, Masahiro Nagai*, Yuji Kumagai*, Tomomichi Fujitani*, Takafumi Okura, et al.

Effect of Renal Impairment on the Pharmacokinetics of Memantine.

Journal of Pharmacological Sciences 119: 324-329,2012.

⇒Detail

Jun Irita, Takafumi Okura, Masanori Jotoku, Tomoaki Nagao, Daijiro Enomoto, Mie Kurata,Veena Rasika Desilva, Ken-ichi Miyoshi, Yutaka Matsui*, Toshimitsu Uede*, David T. Denhardt*, Susan R. Rittiling*, Jitsuo Higaki.

Osteopontin Dificiency Protects Against Aldosterone-Induced Inflammation, Oxidative Stress, and Interstitial Fibrosis in the Kidney.

American Journal of Physiology Renal Physiology 301: E833-844,2011.

⇒Detail

Mie Kurata, Takafumi Okura, Jun Irita, Daijiro Enomoto, Tomoaki Nagao, Masanori Jotoku, Ken-ichi Miyoshi, Veena Rasika Desilva, Jitsuo Higaki.

AngiotensinⅡReceptor Blockade with Valsartan Decreases Plasma Osteopontin Levels in Patients with Essential Hypertension.

Journal of Human Hypertension 25: 334-339,2011.

⇒Detail

Zuowei Pei, Takafumi Okura, Ken-ichi Miyoshi, Toshio Honda*, Junji Doiuchi*,
Masayuki Takezaki*, Hirokazu Takahashi*, Shousein Nagaoka*, Jitsuo Higaki.

Effects of Telmisartan on Metabolic Parameters in Patients with Essential Hypertension.

Ehime Medical Journal 30: 30-34,2011.

Masunori Matsuzaki*, Toshio Ogihara*, Seiji Umemoto*, Hitomi Rakugi*, Hiroaki Matsuoka*, Kazuyuki Shimada*, Keishi Abe*, Norihiro Suzuki*, Tanenao Eto*,Jitsuo Higaki, Sadayoshi Ito*, Akira Kamiya*, Kenjiro Kikuchi*, Hiromichi Suzuki*, Chuwa Tei*, Yasuo Ohashi*, T
akao Saruta*, for the Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group.

Prevention of Cardiovascular Events with Calcium Channel Blocker-Based Combination Therapies in Patients with Hypertension: A Randomized Controlled Trial.

Journal of Hypertension 29: 1649-1659,2011

⇒Detail

Kazuki Ohno*, Yasushi Amano*, Hirotoshi Kakuta*, Tatsuya Niimi*, Shoji Takakura*,
Masaya Orita*, Kenji Miyata*, Hitoshi Sakashita*, Makoto Takeuchi*, Issei Komuro*,
Jitsuo Higaki, Masatsugu Horiuchi*, Shokei Kim-Mitsuyama*, Ryuichi Morishita*,
Sho-ichi Yamaguchi*.

Unique“Delta Lock” Structure of Telmisartan in Involved in Its Strongest Binding Affinity to AngiotensinⅡ Type 1 Receptor.

Journal of Hypertension 29: 1649-1659,2011.

⇒Detail